Member Info for Iknownuffin

Coco - your obsession with certain posters is very unhealthy I must say and quite boring indeed.

ECR is going from strength to strength from when new management came in.

Bull, the x spaces was not recorded. But have a look at this link which is explaining next steps taken by shareholders.

https://x.com/dds_docholiday/status/2032717842018107647?s=46&t=xWu6VRtKQKEpOSEs6eUnvg

“ Apart from I clearly stated that I didn't take part in the PYC WRAP in a post earlier this morning.“

Sadly I haven’t seen such a post, just going off your last message 👍

I have no need to discredit as I have no care what anyone is doing or investing in.

“ you mean I had anything to do with the placing or even took part, No, I have never taken part in a placing, I have with open offers and WRAP type things but never a placing“

Clever way of saying you have participated in the Wrap over the last few days then 🤦‍♂️😂😂

Yes sorry it’s dilution 👍

TG selling down is not a good sign however it’s spun.

Https://x.com/i/status/2032365602728214821

Spaces chat including PYC 9:30 am today. Lets hear what the plan is.

Yes agree, 30% discount ( irrelevant of following previous raises ) is not good. Many think they can do better so let’s see if this can happen.

Some are very much obsessed here 🤦‍♂️

Wrap offer very much shows the appetite is there for this company. Next few weeks will be interesting indeed.

Little different when directors involved eh 👍

Obviously JB is doing well then yes ? Playing the “ game “ just right 👊

D, it’s like you are the messiah sent to help all investors.

You are here to make money like all of us and you couldn’t care less about the companies you invest in.

If you ain’t invested here then move on, it’s a complete waste of your time & life 👍

Life is bizarre, AIM is on another level. Like I said hate the game and not the player, it eats away and very much pointless indeed. 👊

No idea why you are calling me doc 🤷‍♂️

I couldn’t give a hoot what he does or how he does such.

How many companies are losing money ?, lifestyle companies and the like that literally rise from the ashes ? Does KEN deserve current valuation ? Has it risen from world order ?, uranium prices ? Asset and so on …..

Either way, I’m not here to argue only to make a couple of bucks, so let’s see which way the wind blows soon 🫡

Hate the game not the player 🫡

PYC will be successful, time will tell indeed the opinion that is bang on 👌

Holding a bag from 2p ? He was tweeting KEN from this time last year so not sure how you have concluded this opinion 🤦‍♂️

Funny that

Big D comes a hating 😂😂

Irrelevant of opinions personally -

ECR was dead before him and a few others got involved.

KEN - 0.24 - 2.5p

MILA - 20 bags in a few months.

Either extremely lucky or can pick some worthy runners.

When investors watch small pharma-services companies like PYC, there’s one signal that often appears before a takeover. It’s not guaranteed, but experienced small-cap investors look for it.

Before a takeover, the small company often starts announcing repeat work with major pharmaceutical companies.

Why this matters:

• Large pharma companies test small specialist firms with small modelling projects first.

• If the work proves valuable, they keep using the company repeatedly.

• Eventually the capability becomes strategically useful, and that’s when a larger CRO or analytics company might think about buying them.

Another thing investors watch is partnership announcements.

If a small modelling company suddenly partners with a major pharma company or a big CRO like:

• IQVIA

• ICON plc

that often means the technology has caught the industry’s attention.

Repeat contracts (a positive signal)

Physiomics has announced follow-on work from existing clients

A follow-on contract from a UK client continuing modelling work for a Phase 2 clinical trial.

A new modelling contract with a South Korean biotech company to support dosing decisions for an oncology drug.

That shows international reach starting to grow.

• Physiomics survived when many AIM biotechs failed

• It now has actual commercial contracts, not just research projects

• The company stayed very lean, avoiding massive cash burn

• The modelling niche is growing in pharma

The real asset of Physiomics is not the contracts themselves.

It’s their pharmacokinetic modelling platform and expertise.

If a larger pharma analytics company wanted that capability, acquiring a tiny company like PYC would be very cheap.

1️⃣ Established scientific credibility

Physiomics isn’t a speculative drug developer.

It provides mathematical modelling for drug development, which pharma companies increasingly rely on to:

• optimise dosing

• reduce trial failures

• shorten development timelines

That’s a real service industry, not a binary “drug works or fails” biotech gamble.

⸻

2️⃣ Recurring contract model

Their revenue tends to come from contracts with pharma and biotech firms.

That means:

• revenue can be lumpy

• but it’s not dependent on one drug approval

Once companies trust the modelling platform, they often come back for further projects.

⸻

3️⃣ Industry trend is in their favour

The whole pharmaceutical industry is moving toward:

• model-informed drug development

• simulation before trials

• AI / computational biology

Companies doing modelling are positioned upstream in the value chain, which can be powerful if demand grows.

⸻

4️⃣ Small wins can move the needle

Because Physiomics is a very small company, even a few new contracts or partnerships can have a large impact on revenue growth.

That’s why microcaps sometimes move dramatically when sentiment changes.